(PASG) – Globe Newswire
-
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
-
Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program
-
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
-
Passage Bio to Participate in Upcoming Investor Conferences
-
Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
-
Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities
-
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
-
Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
-
Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference
-
Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference
-
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference
-
Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights
-
Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study
-
Passage Bio to Participate in Upcoming Investor Conferences
-
Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors
-
Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference
-
Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights
-
Passage Bio Announces Recipient of Second Annual Tachi Yamada Scholarship Award
-
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
-
Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
-
Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days
-
Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days
-
Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights
-
Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights
-
Passage Bio Seeks Pennsylvania College Student Candidates for Second Annual Tachi Yamada Scholarship Program
-
Passage Bio to Present at Cowen 43rd Annual Health Care Conference
-
Passage Bio to Present at Cowen 43rd Annual Health Care Conference
-
Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023
-
Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023
-
Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023
-
Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023
-
Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023
-
Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023
-
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study
-
Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study
-
Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates
-
Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates
-
Passage Bio to Present at Guggenheim 4th Annual Immunology & Neurology Day
-
Passage Bio to Present at Guggenheim 4th Annual Immunology & Neurology Day
-
Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022
-
Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022
-
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer
-
Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer
Back to PASG Stock Lookup
